Perspective Therapeutics, Inc.CATXNYSE
Loading
Year-over-year SG&A expense growth
Percentile
P23
Within normal range
vs 5Y Ago
-1.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -10.09% |
| Q3 2025 | 0.29% |
| Q2 2025 | -1.70% |
| Q1 2025 | -4.90% |
| Q4 2024 | 18.22% |
| Q3 2024 | 26.50% |
| Q2 2024 | -6.19% |
| Q1 2024 | 246.99% |
| Q4 2023 | -69.48% |
| Q3 2023 | -7.24% |
| Q2 2023 | -23.62% |
| Q1 2023 | 161.78% |
| Q4 2022 | -23.53% |
| Q3 2022 | 75.04% |
| Q2 2022 | -1.41% |
| Q1 2022 | -2.24% |
| Q4 2021 | -10.80% |
| Q3 2021 | 31.96% |
| Q2 2021 | 11.73% |
| Q1 2021 | 0.92% |
| Q4 2020 | 6.07% |
| Q3 2020 | -14.96% |
| Q2 2020 | -1.12% |
| Q1 2020 | 12.84% |
| Q4 2019 | -9.15% |
| Q3 2019 | 13.67% |
| Q2 2019 | -3.56% |
| Q1 2019 | -3.27% |
| Q4 2018 | 11.16% |
| Q3 2018 | -27.43% |
| Q2 2018 | 51.53% |
| Q1 2018 | -11.09% |
| Q4 2017 | 14.02% |
| Q3 2017 | -28.85% |
| Q2 2017 | 50.92% |
| Q1 2017 | -1.53% |
| Q4 2016 | -5.17% |
| Q3 2016 | -4.54% |
| Q2 2016 | 25.60% |
| Q1 2016 | -12.25% |